986 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Alpine Bank Wealth Management

Alpine Bank Wealth Management purchased a new stake in AstraZeneca PLC (NASDAQ:AZN) in the first quarter, HoldingsChannel reports. The fund purchased 986 shares of the company’s stock, valued at approximately $72,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Confluence Investment Management LLC bought a new stake in shares of AstraZeneca during the first quarter valued at approximately $27,000. FNY Investment Advisers LLC acquired a new stake in AstraZeneca during the first quarter worth $29,000. Banque Transatlantique SA bought a new stake in AstraZeneca in the 4th quarter valued at $26,000. Highline Wealth Partners LLC raised its stake in shares of AstraZeneca by 447.4% in the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock valued at $31,000 after buying an additional 340 shares in the last quarter. Finally, Mascagni Wealth Management Inc. bought a new position in shares of AstraZeneca during the 4th quarter worth about $29,000. 20.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, BNP Paribas began coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $85.00.

AstraZeneca Price Performance

Shares of AZN stock opened at $69.68 on Thursday. The stock’s fifty day simple moving average is $70.50 and its 200 day simple moving average is $70.45. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The firm has a market cap of $216.10 billion, a price-to-earnings ratio of 27.98, a P/E/G ratio of 1.29 and a beta of 0.38. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the previous year, the company earned $2.06 EPS. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. On average, analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.